Sorting through immunomodulatory psoriasis agents

Norman Levine, M.D., professor and chief of dermatology, University of Arizona, and Gerald G. Krueger, M.D., professor of dermatology, Cumming Presidential Endowed Chair, University of Utah, discuss immunomodulatory agents in the treatment of psoriasis.

Related Videos
Related Content

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

AAD 2023 Pearls from Zoe Diana Draelos, MD

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

AAD 2023 Pearls from Zoe Diana Draelos, MD

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

AAD 2023 Pearls from Zoe Diana Draelos, MD

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.